The present invention provides a liquid aqueous formulation for the intranasaladministration of apomorphine, whichcomprises: (a) at least about 15 mg/ml of apomorphine； and (b) a solubilisingagent selected from (i) at least onepolyoxyethylene-polyoxypropylene copolymer (poloxamer)； (ii) at least onecyclodextrin； and (iii) at least one cyclodextrin together with chitosan.The formulations of the invention can be used in the treatment/management ofParkinson's disease.
